Predicting the development of liver cirrhosis by simple modelling in patients with chronic hepatitis C

Data are scarce on the natural history of chronic hepatitis C (CHC) in patients with mild hepatitis C who did not respond to anti‐viral therapy.

[1]  Jean-Michel Pawlotsky,et al.  EASL Recommendations on Treatment of Hepatitis C 2018. , 2018, Journal of hepatology.

[2]  L. Henry,et al.  Systematic review: patient‐reported outcomes in chronic hepatitis C ‐ the impact of liver disease and new treatment regimens , 2015, Alimentary pharmacology & therapeutics.

[3]  M. Trauner,et al.  Successful anti‐viral treatment improves survival of patients with advanced liver disease due to chronic hepatitis C , 2015, Alimentary pharmacology & therapeutics.

[4]  Brian L. Pearlman,et al.  Simeprevir plus sofosbuvir, with or without ribavirin, to treat chronic infection with hepatitis C virus genotype 1 in non-responders to pegylated interferon and ribavirin and treatment-naive patients: the COSMOS randomised study , 2014, The Lancet.

[5]  K. Kotoh,et al.  Hepatocarcinogenesis in chronic hepatitis C patients achieving a sustained virological response to interferon: significance of lifelong periodic cancer screening for improving outcomes , 2014, Journal of Gastroenterology.

[6]  O. Weiland,et al.  ABT-450, ritonavir, ombitasvir, and dasabuvir achieves 97% and 100% sustained virologic response with or without ribavirin in treatment-experienced patients with HCV genotype 1b infection. , 2014, Gastroenterology.

[7]  S. Bertrais,et al.  Evolution of noninvasive tests of liver fibrosis is associated with prognosis in patients with chronic hepatitis C , 2014, Hepatology.

[8]  S. Bertrais,et al.  Combination of blood tests for significant fibrosis and cirrhosis improves the assessment of liver‐prognosis in chronic hepatitis C , 2014, Alimentary pharmacology & therapeutics.

[9]  Riina Salupere,et al.  Sofosbuvir and ribavirin in HCV genotypes 2 and 3. , 2014, The New England journal of medicine.

[10]  M. Manns,et al.  Reliable prediction of clinical outcome in patients with chronic HCV infection and compensated advanced hepatic fibrosis: a validated model using objective and readily available clinical parameters , 2014, Gut.

[11]  H. Mo,et al.  Sofosbuvir and ledipasvir fixed-dose combination with and without ribavirin in treatment-naive and previously treated patients with genotype 1 hepatitis C virus infection (LONESTAR): an open-label, randomised, phase 2 trial , 2014, The Lancet.

[12]  A. Lok,et al.  Daclatasvir plus sofosbuvir for previously treated or untreated chronic HCV infection. , 2014, The New England journal of medicine.

[13]  T. Berg,et al.  Evaluation of liver disease progression in the German hepatitis C virus (1b)‐contaminated anti‐D cohort at 35 years after infection , 2014, Hepatology.

[14]  J. Bosch,et al.  Non-Invasive Diagnostic and Prognostic Evaluation of Liver Cirrhosis and Portal Hypertension , 2011, Disease markers.

[15]  Laurent Castera,et al.  Non-invasive evaluation of liver fibrosis using transient elastography. , 2008, Journal of hepatology.

[16]  L. Seeff,et al.  Natural history of chronic hepatitis C , 2002, Hepatology.

[17]  E. Schiff,et al.  Sampling error and intraobserver variation in liver biopsy in patients with chronic HCV infection , 2002, American Journal of Gastroenterology.

[18]  Kenneth Koury,et al.  For Personal Use. Only Reproduce with Permission from the Lancet Publishing Group , 2022 .

[19]  R. Testa,et al.  Increased Levels of γGT Suggest the Presence of Bile Duct Lesions in Patients with Chronic Hepatitis C , 2001, Digestive Diseases and Sciences.

[20]  P. Bedossa,et al.  Ultrasonographic diagnosis of hepatic fibrosis or cirrhosis. , 1999, Journal of hepatology.

[21]  F. Gordon,et al.  AST/ALT Ratio Predicts Cirrhosis in Patients With Chronic Hepatitis C Virus Infection , 1998, American Journal of Gastroenterology.

[22]  L. Bolondi,et al.  What is the criterion for differentiating chronic hepatitis from compensated cirrhosis? A prospective study comparing ultrasonography and percutaneous liver biopsy. , 1997, Journal of hepatology.

[23]  P. Bedossa,et al.  Intraobserver and Interobserver Variations in Liver Biopsy Interpretation in Patients with Chronic Hepatitis C , 1994 .

[24]  J. Pawlotsky,et al.  EASL Recommendations on Treatment of Hepatitis C 2015. , 2015, Journal of hepatology.

[25]  William M. Lee,et al.  Predicting clinical and histologic outcomes based on standard laboratory tests in advanced chronic hepatitis C. , 2010, Gastroenterology.

[26]  R. Testa,et al.  Increased levels of gammaGT suggest the presence of bile duct lesions in patients with chronic hepatitis C: absence of influence of HCV genotype, HCV-RNA serum levels, and HGV infection on this histological damage. , 2001, Digestive diseases and sciences.